Please contact us for any questions or request for reagents for this structure.

human START domain containg 13

Click on the iSee icon to launch an enhanced annotation with interactive 3D representations and animated transitions. Please note that a web plugin (activeICM) is required to access this enhanced functionality. Instructions for the installation and use of the web plugin are available.

PDB Code 2PSO Target Class Lipid signalling Target STARD13 Alias DLC2, FLJ37385, GT650, STARD13 Disease Area/Function cancer Date Deposited May 07 2007 Authors L.LEHTIO, R.BUSAM, C.H.ARROWSMITH, H.BERGLUND, R.COLLINS, L.G.DAHLGREN, A.EDWARDS, S.FLODIN, A.FLORES, S.GRASLUND, M.HAMMARSTROM, B.M.HALLBERG, L.HOLMBERG-SCHIAVONE, I.JOHANSSON, A.KALLAS, T.KARLBERG, T.KOTENYOVA, M.MOCHE, P.NORDLUND, T.NYMAN, D.OGG, J.SAGEMARK, P.STENMARK, M.SUNDSTROM, A.G.THORSELL, S.VANDEN BERG, J.WEIGELT, M.WELIN, C.PERSSON, STRUCTURAL GENOMICSCONSORTIUM (SGC)

About this structure

Steroidogenic acute regulatory protein-related lipid transfer (START) domain containing protein 13 (STARD13), also known as deleted in liver cancer 2 (DLC-2) is a growth suppressor protein commonly deleted in hepatocellular carcinoma (HCC) and other cancers. The protein exhibit its tumor suppression functions in vivo as a GAP specific for RhoA, exerting its effects in suppression of cytoskeleton reorganization, cell growth, cell migration, and transformation. The START domain is a well-conserved lipid binding domain present in 15 distinct human proteins, either alone or in combinations with other domains. The START domain of STARD13 steers DLC2 to specific biological membranes as the mitochondrial membrane and specific lipid droplets, implicating a role of STARD13 in mitochondrial lipid transport.

References

  1. Alpy F, Tomasetto C. Give lipids a START: the StAR-related lipid transfer (START) domain in mammals. J Cell Sci. 2005 Jul 1;118(Pt 13):2791-801. Review.
  2. Ng DC, Chan SF, Kok KH, Yam JW, Ching YP, Ng IO, Jin DY. Mitochondrial targeting of growth suppressor protein DLC2 through the START domain. FEBS Lett. 2006 Jan 9;580(1):191-8.
  3. Leung TH, Ching YP, Yam JW, Wong CM, Yau TO, Jin DY, Ng IO. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):15207-12.
  4. Ching YP, Wong CM, Chan SF, Leung TH, Ng DC, Jin DY, Ng IO. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem. 2003 Mar 21;278(12):10824-30.